A novel medication, the drug , is generating significant buzz within the healthcare community as a possible treatment for weight challenges. Developed by Eli Lilly , it’s a twin GIP and GLP-1 target agonist, meaning it functions on two different pathways to regulate appetite and encourage energy utilization. Early trial findings have demonstrated